Alpha 2.0
Login Register
» Authors » Lorena Rentero Redondo

Lorena Rentero Redondo

Explore the profile of Lorena Rentero Redondo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 14
Followers 0
Related Specialties
Gastroenterology
Nutritional Sciences
Top 10 Co-Authors
Carles Iniesta Navalon
Isabel Nicolas de Prado
Rosa Gomez Espin
Mayte Gil Candel
Lidia Serrano Diaz
Juan Jose Gascon Canovas
Carmen Sanchez Alvarez
Cristina Tomas Jimenez
Elena Urbieta Sanz
Ignacio Salar Valverde
Published In
Rev Esp Enferm Dig
Gastroenterol Hepatol
Nutr Hosp
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study
Serrano Diaz L, Iniesta Navalon C, Gomez Espin R, de Prado I, Bernal Morell E, Rentero Redondo L
Gastroenterol Hepatol . 2023 Aug; 47(6):553-561. PMID: 37597745
Background: Studies have investigated the efficacy and safety of switching to the biosimilar infliximab (CT-P13) in patients with inflammatory bowel disease (IBD). However, there is limited research directly comparing the...
2.
Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease
Serrano Diaz L, Iniesta Navalon C, Gomez Espin R, de Prado I, Rentero Redondo L
Gastroenterol Hepatol . 2022 Nov; 46(7):504-511. PMID: 36400260
Background And Objectives: There is increasing evidence that proactive monitoring is useful in improving the control of inflammatory bowel disease, although it remains controversial. The aim of this study was...
3.
Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival
Iniesta Navalon C, Gil Candel M, Salar Valverde I, de Prado I, Gomez Espin R, Rentero Redondo L
Rev Esp Enferm Dig . 2021 Jan; 113(11):770-775. PMID: 33486961
Background: efficacy and safety were evaluated after switching to a biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD). However, few cohort studies compare the pharmacokinetic profiles, immunogenicity, and...
4.
Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study
Gomez Espin R, de Prado I, Gil Candel M, Gonzalez Carrion M, Rentero Redondo L, Iniesta Navalon C
Rev Esp Enferm Dig . 2020 Nov; 113(2):110-115. PMID: 33213170
Introduction: numerous studies have shown a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes during the induction and maintenance period in patients with Crohn's disease (CD). To...
5.
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients
Gil Candel M, Gascon Canovas J, Gomez Espin R, de Prado I, Rentero Redondo L, Sanz E, et al.
Rev Esp Enferm Dig . 2020 Jul; 112(8):590-597. PMID: 32686429
Introduction: infliximab is used in inflammatory bowel disease, which has a great inter-individual pharmacokinetic variability. Thus, it is necessary to individualize the therapy in many cases. The main objective of...
6.
[MALNUTRITION IN THE ELDERLY PATIENT TO HOSPITAL ADMISSION, AN OLD PROBLEM UNSOLVED]
Rentero Redondo L, Iniesta Navalon C, Gascon Canovas J, Tomas Jimenez C, Sanchez Alvarez C
Nutr Hosp . 2015 Nov; 32(5):2169-77. PMID: 26545674
Objetive: to determine the prevalence of malnutrition in patients aged 65 years or more at admission and factors associated with its presence. Analyze excess hospital stay (EHS), economic impact and...